Neuralstem to Collaborate with University of Michigan ALS Clinic
to Explore Neuralstem Cells' Potential in Lou Gehrig's Disease
Treatment
ROCKVILLE, Md., Aug. 30 /PRNewswire-
company,
Neuralstem, Inc. (Amex: CUR), today announced it has entered into a
collaborative agreement with the ALS Clinic at University of Michigan
Health System, directed by Dr. Eva Feldman, M.D., Ph.D., the De Jong
Professor of Neurology at the U-M Medical School. The goal of the
collaboration is to provide further proof-of-principle data to move
Neuralstem's spinal cord stem cells into patients with Amyotrophic
Lateral
Sclerosis (ALS), or Lou Gehrig's disease. ALS is a motor neuron
disease,
which strikes people between the ages of 40 and 70. As many as 30,000
Americans have the disease at any given time.
"We are honored and excited to be working with Dr. Feldman and the
University of Michigan ALS Clinic," said Neuralstem CEO, Richard
Garr. "It
is not only a world class research organization, but also clearly
dedicated
to, and deeply involved in, the care and treatment of the ALS patients
themselves. Dr. Feldman and her team will be a tremendous partner in
helping us to achieve our goal, which is to be able to treat ALS
patients
with our Neuralstem cells."
"We are excited about working with Neuralstem's technology and
exploring the ways in which it might lead to treatment for ALS
patients,"
said Dr. Feldman, who is also the Director at the U-M Program for
Neurology
Research and Discovery, "At the Michigan ALS clinic, we are working
as hard
and as fast as we can to try to find treatments for this terrible
disease."
About Neuralstem
Neuralstem's patent-protected technology enables, for the first
time,
the ability to produce neural stem cells of the human brain and
spinal cord
in commercial quantities, and the ability to control the
differentiation of
these cells into mature, physiologically relevant human neurons and
glia.
The Company expects that its first Investigational New Drug (IND)
application will be for the treatment of Ischemic Paraplegia, a form
of
paraplegia that sometimes results from the surgery to repair aortic
aneurysms and for which there is no effective treatment. The Company
hopes
to submit its initial IND application to the FDA and begin its first
human
trial during calendar year 2007.
Major Central Nervous System diseases targeted by the Company with
research programs currently underway include: Ischemic Paraplegia,
Traumatic Spinal Cord Injury, ALS, and Parkinson's disease. The
company's
cells recently extended the life of rats with ALS (Lou Gehrig's
disease) in
a paper published in the journal TRANSPLANTATION, and were deemed
viable
for continued work in neurodegenerative spinal conditions. Neuralstem
cells
also recently reversed paralysis in rats with Ischemic Spastic
Paraplegia,
a form of paralysis that can result from the surgery to repair aortic
aneurysms, as reported in NEUROSCIENCE (http://www.neurosci
ibro.com/
). The company has also developed immortalized human neural stem
cells for
in-vitro use in drug development for the academic and pharmaceutical
markets. For further information, please visit
http://www.neuralst
Cautionary Statement Regarding Forward Looking Information
This presentation may contain forward-looking information about
Neuralstem, Inc. which are intended to be covered by the safe harbor
for
forward-looking statements provided by the Private Securities
Litigation
Reform Act of 1995. Forward- looking statements are statements that
are not
historical facts. These statements can be identified by the use of
forward-
looking terminology such
as "believe," "expect," "may," "will," "should,"
"project," "plan," "seek," "intend," or "anticipate" or the negative
thereof or comparable terminology, and include discussions of
strategy, and
statements about industry trends and Neuralstem's future performance,
operations and products. This and other "Risk Factors" contained in
Neuralstem's public filings with the SEC should be read in connection
with
this release. For further information on Neuralstem, please review the
company's filings with the SEC including its Annual Report filed on
Form
10-KSB for the period ended December 31, 2006, as well as the
company's
subsequent filings.
SOURCE Neuralstem, Inc.
http://www.prnewswi
ACCT=104&STORY=
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
